Abstract:The equilibrium between histone acetylation and deacetylation plays an important role in cancer initiation and progression. The histone deacetylases (HDACs) are a class of key regulators of gene expression that enzymatically remove an acetyl moiety from acetylated lysine ε-amino groups on histone tails. Therefore, HDAC inhibitors have recently emerged as a promising strategy for cancer therapy and several pan-HDAC inhibitors have globally been approved for clinical use. In the present study, we designed and synthesized a series of substituted indole-based hydroxamic acid derivatives that exhibited potent anti-proliferative activities in various tumor cell lines. Among the compounds tested, compound 4o, was found to be among the most potent in the inhibition of HDAC1 (half maximal inhibitory concentration, IC50 = 1.16 nM) and HDAC6 (IC50 = 2.30 nM). It also exhibited excellent in vitro anti-tumor proliferation activity. Additionally, compound 4o effectively increased the acetylation of histone H3 in a dose-dependent manner and inhibited cell proliferation by inducing cell cycle arrest and apoptosis. Moreover, compound 4o remarkably blocked colony formation in HCT116 cancer cells. Based on its favorable in vitro profile, compound 4o was further evaluated in an HCT116 xenograft mouse model, in which it demonstrated better in vivo efficacy than the clinically used HDAC inhibitor, suberanilohydroxamic acid. Interestingly, compound 4k was found to have a preference for the inhibition of HDAC6, with IC50 values of 115.20 and 5.29 nM against HDAC1 and HDAC6, respectively.

Development of 3-Hydroxycinnamamide-based HDAC Inhibitors with Potent in Vitro and in Vivo Anti-Tumor Activity

Development of N-Hydroxycinnamamide-Based Hdac Inhibitors with Improved Hdac Inhibitory Activity and in Vitro Antitumor Activity

Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.

Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.

Development of N-Hydroxycinnamamide-Based Histone Deacetylase Inhibitors with an Indole-Containing Cap Group

Design, synthesis, and in vitro biological evaluation of novel HDAC inhibitors bearing C-1 phenyl substituted tetrahydroisoquinoline Cap moiety as anti-tumor therapeutic agents

Design, synthesis and biological evaluation of coumarin-based N-hydroxycinnamamide derivatives as novel histone deacetylase inhibitors with anticancer activities

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities

Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors

Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities.

Development of N-hydroxybenzamide Derivatives with Indole-Containing Cap Group As Histone Deacetylases Inhibitors

Synthesis and Biological Evaluation of Thiophene-Based Hydroxamate Derivatives As HDACis with Antitumor Activities

Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities

Development of Hydroxamate-Based Histone Deacetylase Inhibitors Containing 1,2,4-Oxadiazole Moiety Core with Antitumor Activities.

Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.

Design, Synthesis and Biological Evaluation of 4-Anilinothieno[2,3-d]pyrimidine-based Hydroxamic Acid Derivatives As Novel Histone Deacetylase Inhibitors.

Design, Synthesis and Biological Evaluation of Isoquinoline-Based Derivatives As Novel Histone Deacetylase Inhibitors

Development of Novel Β-Carboline-based Hydroxamate Derivatives As HDAC Inhibitors with DNA Damage and Apoptosis Inducing Abilities.

Design, Synthesis and Biological Evaluation of Quinoline Derivatives As HDAC Class I Inhibitors.

Design, synthesis and antitumor activity evaluation of novel benzamide HDAC inhibitors

Discovery of 1,2,4-Oxadiazole-containing Hydroxamic Acid Derivatives As Histone Deacetylase Inhibitors Potential Application in Cancer Therapy.